Steatotic liver disease has emerged as an important risk factor for cardiovascular disease, type 2 diabetes mellitus and chronic kidney disease. Successful treatment of steatotic liver disease might also be effective in preventing these cardiometabolic diseases.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Roden, M. & Shulman, G. I. The integrative biology of type 2 diabetes. Nature 576, 51–60 (2019).
Targher, G., Tilg, H. & Byrne, C. D. Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. Lancet Gastroenterol. Hepatol. 6, 578–588 (2021).
Rinella, M. E. et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology https://doi.org/10.1016/j.aohep.2023.101133 (2024).
Ren, Z., Simons, P. I. H. G., Wesselius, A., Stehouwer, C. D. A. & Brouwers, M. C. G. J. Relationship between NAFLD and coronary artery disease: a Mendelian randomization study. Hepatology 77, 230–238 (2023).
Stefan, N., Schick, F., Birkenfeld, A. L., Häring, H.-U. & White, M. F. The role of hepatokines in NAFLD. Cell Metab. 35, 236–252 (2023).
Cao, Y. et al. Liver–heart cross-talk mediated by coagulation factor XI protects against heart failure. Science 377, 1399–1406 (2022).
Aminian, A. et al. Association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis. JAMA 326, 2031–2042 (2021).
Harrison, S. A., Allen, A. M., Dubourg, J., Noureddin, M. & Alkhouri, N. Challenges and opportunities in NASH drug development. Nat. Med. 29, 562–573 (2023).
Mantovani, A., Byrne, C. D. & Targher, G. Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium–glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review. Lancet Gastroenterol. Hepatol. 7, 367–378 (2022).
Loomba, R. et al. Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH. N. Engl. J. Med. 389, 998–1008 (2023).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
N.S. declares that he has received speaker honoraria from AstraZeneca, Boehringer-Ingelheim, Bristol Myers Squibb, Genkyotex, Intercept Pharma, Lilly, Merck Sharp & Dohme, Novo Nordisk, Pfizer and Sanofi, has received research funding from AstraZeneca, DSM Nutritional Products, F. Hoffmann-La Roche and Sanofi, and has acted as an advisor for AstraZeneca, Genkyotex, GlaxoSmithKline Biologicals, Intercept Pharma, Lilly, Novo Nordisk, Pfizer and Sanofi. The other authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Stefan, N., Lonardo, A. & Targher, G. Role of steatotic liver disease in prediction and prevention of cardiometabolic diseases. Nat Rev Gastroenterol Hepatol 21, 136–137 (2024). https://doi.org/10.1038/s41575-023-00880-2
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41575-023-00880-2